Skip to main content
. 2009 Jul 27;114(14):3008–3017. doi: 10.1182/blood-2008-04-148643

Figure 5.

Figure 5

Inhibition of AML cell migration, adhesion, and proliferation in vitro. (A) OCI-AML3 cells treated with 200 μmol/L peptide or 20 μmol/L small-molecule were allowed to migrate through an endothelial-cell monolayer. The results show means ± SD from triplicate wells. *P < .001 by Student t test. (B) Cells pretreated with RNAi oligomers were assessed as in panel A; *P < .001. (C) AML-M4 primary human leukemia-derived cells were subjected to migration in collagen-coated chambers for 24 hours, and the migrated cells were counted. DMSO indicates dimethylsulfoxide. *P < .05. (D) AML-M4 primary human leukemia-derived cells were allowed to bind to gelatin-coated microtiter wells for 60 minutes after which the bound cells were determined via the DHL assay; *P < .001. (E) AML-M4 primary cells were cultivated in suspension for 7 days with the compounds as described and the growth was determined via the DHL assay; *P < .02. (F) OCI-AML3 cells were cultivated in suspension for 24 hours or 48 hours, and the growth was determined via the DHL assay; *P < .01.